Dana Farber Cancer Institute – Amyloidosis Program

The Amyloidosis Program at Dana-Farber and Brigham and Women’s Hospital is highly specialized and dedicated to the diagnosis, research, and treatment of this underappreciated and often misdiagnosed disease. Our approach to treatment is unique in that it is grounded in science and laboratory-based discovery.

Our program works closely with patients and referring physicians to provide access to the newest clinical trials, innovative therapies, and a level of quality, compassionate, patient-centered care that is unparalleled in cancer care.
There are several amyloid diseases. Here, we focus mainly on AL (light chain) amyloidosis — a subtype related to the production of amyloidogenic free light chains by abnormal plasma cells within the bone marrow. Our colleagues at Brigham and Women’s Hospital provide care for other forms of amyloidosis, which generally do not require oncologic care.